Sugi Predict

Sugi Predict / Targets / DNTT

DNTT

DNA nucleotidylexotransferase · P04053 · DNTT on Sugi Atlas →

919 patent compounds predicted against DNTT, 249 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Untenone A Untenone A (SCHEMBL29472169) 1.00 7/20
SCHEMBL30844860 SCHEMBL30844860 0.59 6/20
SCHEMBL29225444 SCHEMBL29225444 0.58 6/20
SCHEMBL30844858 SCHEMBL30844858 0.58 6/20
SCHEMBL28659104 SCHEMBL28659104 0.53 5/20
SCHEMBL15994429 SCHEMBL15994429 0.48 4/20
SCHEMBL10621668 SCHEMBL10621668 0.66 3/20
SCHEMBL19720143 SCHEMBL19720143 0.57 3/20
SCHEMBL31534656 SCHEMBL31534656 0.51 3/20
SCHEMBL11156785 SCHEMBL11156785 0.38 3/20
SCHEMBL11161243 SCHEMBL11161243 0.38 3/20
SCHEMBL29236104 SCHEMBL29236104 0.37 3/20
SCHEMBL30080834 SCHEMBL30080834 0.37 3/20
SCHEMBL15763644 SCHEMBL15763644 0.36 3/20
SCHEMBL10713033 SCHEMBL10713033 0.48 2/20
SCHEMBL10714235 SCHEMBL10714235 0.48 2/20
SCHEMBL19680126 SCHEMBL19680126 0.45 2/20
SCHEMBL114297 SCHEMBL114297 0.45 2/20
Hexane Hexane (SCHEMBL28238285) 0.44 2/20
SCHEMBL8148592 SCHEMBL8148592 0.44 2/20

Clinical trials — most relevant to DNTT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PREventing Progression of Adipose Tissue Redistribution PHASE4COMPLETED
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment PHASE4COMPLETED
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis PHASE3COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection PHASE3UNKNOWN
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer PHASE2UNKNOWN
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung PHASE2COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma PHASE2UNKNOWN
Low-Dose Danazol for the Treatment of Telomere Related Diseases PHASE2COMPLETED
Capecitabine and Temozolomide for Neuroendocrine Cancers PHASE2COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers PHASE1COMPLETED
FdCyd and THU for Advanced Solid Tumors PHASE1COMPLETED
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older EARLY_PHASE1UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Accelerated Aging, HIV Infection, Antiretroviral Therapies nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Characterization of Sperm Population Following Different Selection Procedures nanUNKNOWN
Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type nanACTIVE_NOT_RECRUITING
Effect of PCR-CRISPR/Cas12a on the Early Anti-infective Schemes in Patients With Open Air Pneumonia nanUNKNOWN
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients nanUNKNOWN
Measurement of Plasma and Intracellular Concentrations of Raltegravir nanCOMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Precision Genomics Medicine Biobank nanRECRUITING
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DNTT binder may also engage these)

ProteinNameSimilarity
P06526 — 1.000 P06526 →
P09838 — 1.000 P09838 →
A4PCD4 — 1.000 A4PCD4 →
Q92089 — 0.997 Q92089 →
O02789 — 0.997 O02789 →
P42118 — 0.995 P42118 →
P36195 — 0.993 P36195 →
O57486 — 0.988 O57486 →
Q9FNY4 — 0.985 Q9FNY4 →
Q67VC8 — 0.975 Q67VC8 →
Q96QE5 — 0.973 Q96QE5 →
A6QPR9 — 0.970 A6QPR9 →
PARP4 Protein mono-ADP-ribosyltransferase PARP4 0.968 landscape →
Q5SSK3 — 0.968 Q5SSK3 →
Q502W6 — 0.968 Q502W6 →
Q5R5S1 — 0.968 Q5R5S1 →
Q9BXT6 — 0.968 Q9BXT6 →
Q5JPI3 — 0.968 Q5JPI3 →
Q15061 — 0.968 Q15061 →
Q7Z7L1 — 0.968 Q7Z7L1 →
Q9JIW4 — 0.967 Q9JIW4 →
O94952 — 0.967 O94952 →
Q08DP1 — 0.967 Q08DP1 →
Q4R6Y8 — 0.967 Q4R6Y8 →
E9PYK3 — 0.967 E9PYK3 →
F1ND48 — 0.966 F1ND48 →
PRMT9 Protein arginine N-methyltransferase 9 0.966 landscape →
P47823 — 0.966 P47823 →
Q68D06 — 0.966 Q68D06 →
Q5RL51 — 0.966 Q5RL51 →